Eli Lilly Dives On Earnings Miss

What You May Have Missed From Eli Lilly's Q3 2024 Earnings Disappointment
LLY’s slashed revenue and earnings guidance for 2024 were a surprise, especially given substantial raises to its outlook observed through 1H24. Read more here.
Eli Lilly Stock Dives Toward Worst Day Since 2000 On Disappointing Earnings, Zepbound Sales
Q3 sales in weight loss drugs Mounjaro and Zepbound were more than 20% lower than consensus analyst forecasts, spooking investors.
Eli Lilly stock sinks after Q3 earnings miss Wall Street expectations
Eli Lilly is set to report Q3 earnings Wednesday, as the pharma giant continues to gain market share in the weight loss drug space.
Eli Lilly Stock Tumbles as Q3 Sales, Profits Fall Well Short of Estimates
Eli Lilly shares sank 10% Wednesday morning after its third-quarter results came in well below what analysts were expecting.
Eli Lilly Q3 earnings expected to beat Wall Street expectations
Eli Lilly is set to report Q3 earnings Wednesday, as the pharma giant continues to gain market share in the weight loss drug space.
Eli Lilly's weight-loss drug misses Wall Street expectations, shares tumble
Eli Lilly missed Wall Street estimates for its popular weight-loss and diabetes drugs on Wednesday, hit by a decrease in U.S. wholesale inventory and sending its shares down 9% premarket. U.S. sales of Mounjaro and Zepbound decreased by mid-single digits due to the inventory changes,
Eli Lilly stock crushed as weight loss sales, profits, disappoint Wall Street
Eli Lilly , which has added more than $300 billion in market value this year, largely on the back of investment optimism for its weight loss treatments, saw its two flagship produ
Eli Lilly Dives On Earnings Miss As Diabetes, Weight-Loss Drugs Fall Short
Eli Lilly earnings and revenue missed Q3 views, with sales light for its diabetes and weight-loss drugs. Eli Lilly stock dived Wednesday.
Eli Lilly misses third-quarter profit amid soaring demand for weight-loss drug
Eli Lilly missed Wall Street estimates for third-quarter profit on Wednesday, even as demand for its weight-loss drug soared, hurt by higher manufacturing and acquisition-related costs.
Eli Lilly (LLY) Q3 2024 Earnings Call Transcript
Operator instructions] I would now like to turn the conference over to your host, Joe Fletcher, senior vice president of ...
Mounjaro's Sales Likely To Rise 2.5x Driving Eli Lilly's Q3 Performance
The pharmaceutical giant is expected to garner $12.1 billion in sales and $1.45 in adjusted earnings per share, per the ...
Taking A Look At Eli Lilly's Q3 2024 Revenue Miss Amid Supply Chain Challenges
LLY had $11.4 billion in revenue for the quarter (up 20% versus Q3 figures from last year), with a net income of $970 million ...
Eli Lilly Q3 Earnings On Deck: Stock Split Rumors Heat Up With Weight Loss Gains (CORRECTED)
Eli Lilly reports Q3 earnings on Wednesday. Stock up 58% in past year, potential to split to attract investors in growing ...
Lawyer Monthly21h
Eli Lilly Shares Tumble After Disappointing Q3 Earnings Report
Eli Lilly shares fell up to 10% after Q3 earnings missed Wall Street expectations, reporting $11.4 billion in revenue and ...
Why Eli Lilly Stock Is Sinking Today
Type 2 diabetes drug Mounjaro and weight-loss drug Zepbound remained the brightest stars in Lilly's lineup. Mounjaro's sales more than doubled year over year to $3.1 billion. Sales for Zepbound, which ...
Eli Lilly Q3 Earnings: Mounjaro Sales More Than Double, Takes $2.98 Billion Hit To Profit, Cuts Annual Outlook, Stock Tanks
Mounjaro sales more than doubled to $3.11 billion from $1.41 billion a year ago. The U.S. pharma giant reported third-quarter ...
Eli Lilly core thesis ‘remains intact’ despite Q3 miss, says JPMorgan
After Eli Lilly (LLY) reported Q3 results that are below the Street view on sales and EPS due to Zepbound and Mounjaro wholesaler destocking ...